Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery.

Autor: Kothiwale S; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA., Borza CM; Department of Medicine, Division of Nephrology, Vanderbilt University, Nashville, TN 37232, USA., Lowe EW Jr; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA., Pozzi A; Department of Medicine, Division of Nephrology, Vanderbilt University, Nashville, TN 37232, USA; Department of Medicine, Veterans Affairs Hospital, Nashville, TN 37232, USA., Meiler J; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA. Electronic address: jens.meiler@vanderbilt.edu.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2015 Feb; Vol. 20 (2), pp. 255-61. Date of Electronic Publication: 2014 Oct 07.
DOI: 10.1016/j.drudis.2014.09.025
Abstrakt: Discoidin domain receptor (DDR) 1 and 2 are transmembrane receptors that belong to the family of receptor tyrosine kinases (RTK). Upon collagen binding, DDRs transduce cellular signaling involved in various cell functions, including cell adhesion, proliferation, differentiation, migration, and matrix homeostasis. Altered DDR function resulting from either mutations or overexpression has been implicated in several types of disease, including atherosclerosis, inflammation, cancer, and tissue fibrosis. Several established inhibitors, such as imatinib, dasatinib, and nilotinib, originally developed as Abelson murine leukemia (Abl) kinase inhibitors, have been found to inhibit DDR kinase activity. As we review here, recent discoveries of novel inhibitors and their co-crystal structure with the DDR1 kinase domain have made structure-based drug discovery for DDR1 amenable.
(Copyright © 2014 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: